IRVINE, CALIFORNIA - OCTOBER 17: The Johnson & Johnson logo is displayed at company offices on October 17, 2023 in Irvine, California. Johnson & Johnson beat Wall Street’s quarterly revenue and earnings estimates as sales in its pharmaceutical and medical devices businesses grew. (Photo by Mario Tama/Getty Images)Getty ImagesOver the past ten years, Johnson & Johnson (NYSE: JNJ) has delivered an impressive $157 Bil back to its investors through cash distributions via dividends and buybacks. This commitment ...

Core Insights - President Trump's tariffs are contributing to significant investments in U.S. manufacturing by major corporations, including semiconductor and pharmaceutical companies [1][3][5] Semiconductor Industry - Taiwan Semiconductor Manufacturing (TSMC) announced a $100 billion investment in U.S. facilities [1] - NVIDIA plans to produce $500 billion worth of AI infrastructure in the U.S. over the next four years [2] Pharmaceutical Industry - Three major pharmaceutical companies are set to invest over $100 billion in the U.S. in the coming years [3] - Roche plans to invest $50 billion in the U.S. over the next five years, expecting to create 12,000 new jobs and export more medicines than it imports [5][6] - Novartis announced a $23 billion investment over the next five years, aiming to produce 100% of its core drugs in the U.S. and create 4,000 jobs [8][10] - Johnson & Johnson is investing more than $55 billion in the U.S. over the next four years, a 25% increase from the previous period, and plans to build three new manufacturing plants [13][14]